logo
Sign In
Farxiga vs. GlyxambiBerinert vs. CinryzeEmgality vs. QuliptaFarxiga vs. InvokanaFirazyr vs. SajazirGlyxambi vs. InvokanaInvokamet vs. SynjardyOpzelura vs. DupixentOrencia vs. RinvoqQulipta vs. VyeptiStelara vs. TremfyaSynjardy vs. VictozaTaltz vs. BimzelxVyepti vs. Nurtec ODTView all Comparisons
ADHD drugsAnxiety drugsAsthma drugsAtopic dermatitis drugsDepression drugsHeart failure drugsHypertension drugsLymphoma drugsOsteoarthritis drugsRheumatoid arthritis drugsRosacea drugsSchizophrenia drugsType 2 Diabetes drugsView all Indications
Bayer drugsAbbVie drugsAstraZeneca drugsEli Lilly and Company drugsGenetech drugsGlaxoSmithKline (GSK) drugsNovartis drugsPfizer drugsTakeda Pharmaceuticals drugsTeva Pharmaceuticals drugsAmgen drugsView all Manufacturers
Beta-Adrenergic BlockerAngiotensin Converting Enzyme InhibitorAngiotensin 2 Receptor BlockerCalcium Channel BlockerDiureticsHMG-CoA Reductase InhibitorProton Pump InhibitorSelective Serotonin Reuptake InhibitorNorepinephrine Reuptake InhibitorBenzodiazepinesOpioid AgonistsNonsteroidal Anti-inflammatory DrugsAntiepileptic AgentsAntipsychoticsAntihistaminesView all Classes
Wegovy®Ozempic®Mounjaro®Zepbound®Jardiance®Farxiga®Dupixent®Trulicity®Lyrica®Lipitor®Effexor®Concerta®Depakote®Trintellix®Rexulti®Rinvoq®Verzenio®Taltz®
For ProvidersRequest DemoJoin Research Panel
For BusinessHCP ChannelCommercial O/SEngageMarketplaceOneHubInsight
Tools & MorePrescribing InfoCoverageSavingsPatient ResourcesA-Z IndicationsCompare Drugs
CompanyAboutInsightsCareersContactSecurity
Legit Script Certified
Get the latest insights in your inbox
Follow us
Legit Script Certified
  • Terms and Conditions
  • Privacy Policy
  • © 2025 PrescriberPoint. All Rights Reserved.

    • Medications for Anemia

    FiltersReset Filters
    8 results

    • azacitidine

      (AZACITIDINE)
      Eugia US LLC
      Usage: Azacitidine for injection is indicated for treating adult patients with specific myelodysplastic syndrome subtypes, including refractory anemia, refractory anemia with ringed sideroblasts (with complications), refractory anemia with excess blasts, and chronic myelomonocytic leukemia. Pediatric use is not labeled due to marketing exclusivity.

    • azacitidine

      (Azacitidine)
      Cipla USA Inc.
      Usage: Azacitidine for injection is indicated for adult patients with myelodysplastic syndromes (MDS), specifically subtypes such as refractory anemia, refractory anemia with ringed sideroblasts, refractory anemia with excess blasts, and chronic myelomonocytic leukemia.

    • cerezyme

      (IMIGLUCERASE)
      Genzyme Corporation
      Usage: Cerezyme is indicated for the treatment of adults and children aged 2 years and older with Type 1 Gaucher disease, addressing conditions such as anemia, thrombocytopenia, bone disease, and hepatomegaly or splenomegaly.

    • desferal

      (deferoxamine mesylate)
      Novartis Pharmaceuticals Corporation
      Usage: DESFERAL is indicated for treating acute iron intoxication and for managing chronic iron overload in patients with chronic anemia. It is not suitable for primary hemochromatosis, where phlebotomy is preferred.

    • ferriprox

      (deferiprone)
      Chiesi USA, Inc.
      Usage: FERRIPROX Tablets are indicated for treating transfusional iron overload in adults and pediatric patients (8 years and older) with thalassemia syndromes, sickle cell disease, or other anemias. Safety and effectiveness are not established for use in myelodysplastic syndrome or Diamond Blackfan anemia.

    • mircera

      (Methoxy polyethylene glycol-epoetin beta)
      Vifor (International) Inc.
      Usage: Mircera is indicated for treating anemia associated with chronic kidney disease in adults (both on and off dialysis) and pediatric patients aged 3 to 17 years transitioning from another ESA. It is not indicated for anemia due to cancer chemotherapy or as a substitute for RBC transfusions.

    • pyridoxine hydrochloride

      (PYRIDOXINE HYDROCHLORIDE)
      Fresenius Kabi USA, LLC
      Usage: Pyridoxine Hydrochloride Injection treats pyridoxine deficiency due to inadequate dietary intake, drug-induced deficiency (e.g., from isoniazid, oral contraceptives), and inborn metabolic errors. It is used parenterally when oral administration is not possible due to conditions like anorexia, nausea, vomiting, or impaired gastrointestinal absorption.

    • retacrit

      (epoetin alfa-epbx)
      Vifor (International) Inc.
      Usage: RETACRIT is indicated for treating anemia due to chronic kidney disease, zidovudine in HIV patients, and chemotherapy-related anemia in cancer patients. It also helps reduce red blood cell transfusions in high-risk surgical patients. It should not be used for certain cancer treatments or when immediate anemia correction is needed.